Showing 1491-1500 of 5771 results for "".
- Yuyu Pharma Announces Topline Results from the ICECAP Phase 1/2 Trial of YP-P10 in Dry Eye Diseasehttps://modernod.com/news/yuyu-pharma-announces-topline-results-from-the-icecap-phase-12-trial-of-yp-p10-in-dry-eye-disease/2481651/Yuyu Pharma announced topline results from the ICECAP phase 1/2 trial of YP-P10 in patients with dry eye disease. ICECAP was the first human, signal-seeking, phase 1/2 trial evaluating the safety and efficacy of YP-P10 over 12 weeks (85 days) of treatment in subjects with dry eye disease, ac
- Aviceda Announces Dosing of First Patient With AVD-104, a Novel Glyco-Mimetic Nanoparticle for the Treatment of GAhttps://modernod.com/news/aviceda-announces-dosing-of-first-patient-with-avd-104-a-novel-glyco-mimetic-nanoparticle-for-the-treatment-of-ga/2481647/Aviceda Therapeutics announced the dosing of its first patient with AVD-104 in its phase 2 SIGLEC trial by Ashkan Abbey, MD, of Texas Retina Associates in Dallas. This lead intravitreal asset is a novel glycan-coated nanoparticle, supported by a uniquely strong preclinical in
- Optos Announces New Ultra-Widefield Color Image Modality, Providing Additional Retinal Visualizationhttps://modernod.com/news/optos-announces-new-ultra-widefield-color-image-modality-providing-additional-retinal-visualization/2481645/Optos announced it is expanding the optomap ultra-widefield (UWF) retinal imaging modalities in the California FA device to further assist eye care professionals in disease management and treatment planning. In addition to optomap color rg (red/green), sensory red-free, c
- Bausch + Lomb Announces Leadership Changeshttps://modernod.com/news/bausch-lomb-announces-leadership-changes/2481644/Bausch + Lomb announced a reshaping of its executive leadership team, including the elevation of all business unit heads. Luc Bonnefoy, senior vice president (SVP), Surgical; John Ferris, SVP, Consumer; and Yang Yang, SVP, Vision Care; will join the executive management team of the comp
- TearRestore Announces First of Its Kind Dry Eye Solutions; Now Available at Walmarthttps://modernod.com/news/tearrestore-announces-first-of-its-kind-dry-eye-solutions-now-available-at-walmart/2481643/TearRestore announced that its Thermal Mask and Eyelid Wipes will now be available at participating Walmart stores nationwide and at Walmart.com. Both products will be available for recommendation for dry eye by Walmart’s in-store optometrists. &ldqu
- Coave Therapeutics Announces Positive 12-Month Data from Ongoing Phase 1/2 Clinical Trial of Investigational RP Drughttps://modernod.com/news/coave-therapeutics-announces-positive-12-month-data-from-ongoing-phase-12-clinical-trial-of-investigational-rp-drug/2481640/Coave Therapeutics announced positive 12-month results from its phase 1/2 trial evaluating the safety and efficacy of its gene therapy, CTx-PDE6b, for retinitis pigmentosa (RP) caused by bi-allelic mutations in the PDE6B gene (PDE6b RP). These positive data support C
- Annexon Announces Topline Data from Phase 2 Trial of ANX007 in Geographic Atrophyhttps://modernod.com/news/annexon-announces-topline-data-from-phase-2-trial-of-anx007-in-geographic-atrophy/2481637/Annexon announced topline results from its ARCHER phase 2 trial of ANX007 in patients with geographic atrophy (GA). The primary endpoint of mean rate of change (slope) in GA lesion area compared to sham at 12 months did not reach statistical significance. A 6.2% reduction in lesion
- Oculis Announces Positive Topline Results from DIAMOND Stage 1 Phase 3 Trial in DME with OCS-01 Eye Dropshttps://modernod.com/news/oculis-announces-positive-topline-results-from-diamond-stage-1-phase-3-trial-in-dme-with-ocs-01-eye-drops/2481628/Oculis announced positive topline results from Stage 1 of its phase 3 DIAMOND trial of OCS-01 eye drops in diabetic macular edema (DME). DIAMOND is a phase 3, two-stage, double-masked, randomized, multicenter trial to assess the efficacy and safety of OCS-01 eye drops in DME
- Sight Sciences Announces 12-Month Results from the First MIGS Comparative Analysis of Real-World Data (RWD) from the IRIS Registryhttps://modernod.com/news/sight-sciences-announces-12-month-results-from-the-first-migs-comparative-analysis-of-real-world-data-rwd-from-the-iris-registry/2481600/Sight Sciences announced the results from a 12-month retrospective sub-analysis of IOP-lowering medication use following the three most commonly performed, FDA approved (or cleared) MIGS procedures in patients with mild stage glaucoma. Analysis included 16,789 patients in 4 different cohorts
- Glaukos Announces FDA Acceptance of NDA Submission for iDose TRhttps://modernod.com/news/glaukos-announces-fda-acceptance-of-nda-submission-for-idose-tr/2481599/Glaukos announced it has received the “Day 74” notification from the FDA acknowledging the previously submitted new drug application (NDA) for iDose TR (travoprost intraocular implant) is sufficiently complete to permit a substantive review. The Prescription Drug U